drugset
drugset / Trial / NCT06162377

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

NCT06162377 ↗

Phase 4 Recruiting 25 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

To learn if OCSCC patients can be safely given methylnaltrexone for 2 weeks before surgery.

Timeline

Start
2024-01-10
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylnaltrexone Other / unclassified — Subcutaneous

Indications

head and neck squamous cell carcinoma